¿Cómo Podemos Ayudarle?

Puede haber opciones para ayudarle a cubrir los gastos de XOLAIR, independientemente del tipo de seguro médico que posea.

Derivación a Fundaciones Independientes de Asistencia al Copago

Si necesita ayuda con el copago de XOLAIR, XOLAIR Access Solutions puede derivarle a una fundación independiente de asistencia al copago.

Una fundación independiente de asistencia al copago es una organización benéfica que proporciona asistencia financiera para medicamentos.

Llame a XOLAIR Access Solutions en el (800) 704-6610 para que le deriven.

Si desea ponerse en contacto directamente con una fundación, puede usar la información que se indica a continuación:

The Assistance Fund, Inc. 
4700 Millenia Boulevard, Suite 410
Orlando, FL 32839
Toll Free: 1-855-845-3663        
https://tafcares.org/

En este momento no hay fondos.

Llame a Genentech Access Solutions en el (866) 4ACCESS /
(866) 422-2377. Quizá le podamos ayudar.

La fundaciones independientes de asistencia al copago tienen sus propias normas para elegibilidad. No podemos garantizarle que una fundación le vaya a ayudar. Solo podemos derivarle para que esta le asista con su estado de salud. Esta información solo se la proporcionamos a modo informativo. No respaldamos ni mostramos preferencia económica por ninguna fundación en particular. Las fundaciones de esta lista no son las únicas que pueden ayudarle.

Derivaciones a la fundación Genentech Patient Foundation

La fundación Genentech® Access to Care Foundation ahora es Genentech Patient Foundation.

Aún nos enfocamos en proporcionar medicamentos gratuitos a los pacientes necesitados, pero hemos realizado algunos cambios para ofrecer mejor asistencia a más pacientes, más rápido.

Genentech Patient Foundation proporciona medicamentos gratuitos a las personas:

  • Que no tienen seguro
  • Cuyo tratamiento no está cubierto por el seguro
  • Que tienen dificultades con sus elevados costos que deben abonar de su bolsillo 

Para obtener más información y solicitar ayuda, visite GenentechPatientFoundation.com.

Si cuenta con cobertura de un seguro médico para su medicamento, primero debe haber probado otros tipos de asistencia a pacientes para ser apto para recibir XOLAIR gratis a través de la Genentech Patient Foundation. Esto incluye el Programa de Copago de XOLAIR y la ayuda de fundaciones independientes de asistencia al copago. También debe cumplir otros criterios financieros. Si no tiene seguro o si su seguro no cubre su medicamento, debe cumplir unos criterios financieros diferentes.

Derivaciones al Programa de Copago de XOLAIR

XOLAIR Access Solutions puede derivarle al Programa de Copago de XOLAIR. Si usted es elegible, puede ayudarle con los gastos de XOLAIR que deba abonar de su bolsillo.

El Programa de Copago de XOLAIR ayuda a los pacientes con un seguro médico comercial. Puede que sea un plan que obtiene a través de su empleador o uno que haya contratado en un Mercado de Seguros Médicos como HealthCare.gov. Para poder calificar, también debe cumplir otros criterios.

Para poder optar al Programa de Copago de XOLAIR, el paciente debe disponer de un seguro comercial, no debe tener Medicare, Medicaid ni ningún otro seguro público y debe cumplir otros criterios de elegibilidad. También debe aceptar las reglas establecidas en los términos y condiciones del programa. Visite XOLAIRCopay.com para ver la lista completa de términos y condiciones.

Cómo Trabajar con XOLAIR Access Solutions

Paso 1

Suscríbase a XOLAIR Access Solutions.

¿Cómo me inscribo?

Paso 2

Trabajamos con usted, con la consulta de su médico, su plan de seguro médico y su farmacia especializada. Podríamos ponernos en contacto con usted para recabar más información.

¿Qué averiguaremos?

Paso 3

Le derivamos a las opciones de asistencia a pacientes.

¿Qué opciones hay?

PAN=siglas en inglés de Autorización del Paciente y Aviso de Solicitud Para Transmitir Información Médica a Genentech Access Solutions y a Genentech® Access to Care Foundation.

SMN=siglas en inglés de Declaración de Necesidad Médica.

Important Safety Information & Indication

What it Treats

XOLAIR® (omalizumab) for subcutaneous use is an injectable prescription medicine used to treat:

  • moderate to severe persistent asthma in patients 6 years of age or older whose asthma symptoms are not controlled by asthma medicines called inhaled corticosteroids. A skin or blood test is performed to see if a patient has allergies to year-round allergens.
  • chronic idiopathic urticaria (CIU; chronic hives without a known cause) in patients 12 years of age and older who continue to have hives that are not controlled by H1 antihistamine treatment

XOLAIR is not used to treat other allergic conditions, other forms of urticaria, acute bronchospasm or status asthmaticus.

Important Safety Information

The most important information patients should know about XOLAIR is that a severe allergic reaction called anaphylaxis can happen when a patient receives XOLAIR. The reaction can occur after the first dose, or after many doses. It may also occur right after a XOLAIR injection or days later. Anaphylaxis is a life-threatening condition and can lead to death. Patients must go to the nearest emergency room right away if they have any of these symptoms of an allergic reaction:

  • wheezing, shortness of breath, cough, chest tightness, or trouble breathing
  • low blood pressure, dizziness, fainting, rapid or weak heartbeat, anxiety, or feeling of “impending doom”
  • flushing, itching, hives, or feeling warm
  • swelling of the throat or tongue, throat tightness, hoarse voice, or trouble swallowing

The patient’s healthcare provider will monitor the patient closely for symptoms of an allergic reaction while they are receiving XOLAIR and for a period of time after the patient’s injection. The patient’s healthcare provider should talk to the patient about getting medical treatment if they have symptoms of an allergic reaction after leaving the healthcare provider’s office or treatment center.

Patients must not receive XOLAIR if they are allergic to omalizumab or any of the ingredients in XOLAIR.

Before receiving XOLAIR, patients must tell their healthcare provider about all of their medical conditions, including if they:

  • have any other allergies (such as food allergy or seasonal allergies)
  • have sudden breathing problems (bronchospasm)
  • have ever had a severe allergic reaction called anaphylaxis
  • have or have had a parasitic infection
  • have or have had cancer
  • are pregnant or plan to become pregnant. It is not known if XOLAIR may harm a patient’s unborn baby
  • are breastfeeding or plan to breastfeed. It is not known if XOLAIR passes into breast milk. Talk with your healthcare provider about the best way to feed your baby while you receive XOLAIR

Patients must tell their healthcare provider about all the medicines they take, including prescription and over-the-counter medicines, vitamins, or herbal supplements.

Receiving XOLAIR

  • XOLAIR should be given by a healthcare provider, in a healthcare setting
  • XOLAIR is given in 1 or more injections under the skin (subcutaneous), 1 time every 2 or 4 weeks
  • In asthma patients, a blood test for a substance called IgE must be performed prior to starting XOLAIR to determine the appropriate dose and dosing frequency
  • In patients with chronic hives, a blood test is not necessary to determine the dose or dosing frequency
  • Patients must not decrease or stop taking any of their other asthma or hive medicine unless their healthcare providers tell them to
  • Patients may not see improvement in their symptoms right away after XOLAIR treatment

Possible side effects of XOLAIR

XOLAIR may cause serious side effects, including:

  • See,“What is the most important information I should know about XOLAIR” in the XOLAIR Medication Guide at http://www.xolair.com regarding the risk of anaphylaxis
  • Cancer. Cases of cancer were observed in some people who received XOLAIR
  • Inflammation of your blood vessels. Rarely, this can happen in people with asthma who receive XOLAIR. This usually, but not always, happens in people who also take a steroid medicine by mouth that is being stopped or the dose is being lowered. It is not known whether this is caused by XOLAIR. Tell your healthcare provider right away if you have rash; chest pain; shortness of breath; or a feeling of pins and needles or numbness of your arms or legs
  • Fever, muscle aches, and rash. Some people who take XOLAIR get these symptoms 1 to 5 days after receiving a XOLAIR injection. If a patient has any of these symptoms, they must tell their healthcare provider
  • Parasitic infection. Some people who are at a high risk for parasite (worm) infections, get a parasite infection after receiving XOLAIR. The patient’s healthcare provider can test the patient’s stool to check if they have a parasite infection
  • Heart and circulation problems. Some people who receive XOLAIR have had chest pain, heart attack, blood clots in the lungs or legs, or temporary symptoms of weakness on one side of the body, slurred speech, or altered vision. It is not known whether this is caused by XOLAIR

The most common side effects of XOLAIR:

  • In adults and children 12 years of age and older with asthma: pain especially in the arms and legs, dizziness, feeling tired, skin rash, bone fractures, and pain or discomfort of the ears
  • In children 6 to less than 12 years of age with asthma: common cold symptoms, headache, fever, sore throat, pain or discomfort of your ear, abdominal pain, nausea, vomiting and nose bleeds
  • In people with chronic idiopathic urticaria: nausea, headaches, swelling of the inside of the nose, throat or sinuses, cough, joint pain, and upper respiratory tract infection

These are not all the possible side effects of XOLAIR. Patients should call their doctor for medical advice about side effects.

Report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch.Report side effects to Genentech at (888) 835-2555 or Novartis Pharmaceuticals Corporation at 888-669-6682.

Please see full Prescribing Information, including Medication Guide, at www.xolair.com for additional Important Safety Information.